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Spinal glial cell activation and cytokine secretion have been implicated in the etiology of neuropathic pain in a number of
experimental models, including diabetic neuropathy. In this study, streptozotocin- (STZ-) induced diabetic rats were either
untreated or treated with gabapentin (50mg/kg/day by gavage for 2 weeks, from 6 weeks after STZ). At 8 weeks after STZ,
hypersensitivity was confirmed in the untreated diabetic rats as a reduced response threshold to touch, whilst mechanical
thresholds in gabapentin-treated diabetic rats were no different from controls. Diabetes-associated thermal hypersensitivity was
also ameliorated by gabapentin. We performed a cytokine profiling array in lumbar spinal cord samples from control and diabetic
rats. This revealed an increase in L-selectin, an adhesion molecule important for neutrophil transmigration, in the spinal cord of
diabetic rats but not diabetic rats treated with gabapentin. Furthermore, we found an increase in the number of neutrophils present
in the parenchyma of the spinal cord, which was again ameliorated in gabapentin-treated diabetic rats. Therefore, we suggest that
dysregulated spinal L-selectin andneutrophil infiltration into the spinal cord could contribute to the pathogenesis of painful diabetic
neuropathy.
1. Introduction
The prevalence of diabetes mellitus is increasing worldwide,
which has significant health and economic implications.
Associated costs include both primary treatment and also
treating the associated secondary complications such as
retinopathy, nephropathy, and neuropathy [1]. Distal sensory
polyneuropathy (DPN) is themost common of the peripheral
nerve disorders associated with diabetes [2]. DPN may be
accompanied by paresthesia such as tingling and burning
sensations, heightened sensitivity to normally innocuous
stimuli, and spontaneous pain. Neuropathic pain serves no
useful function [3] and is a debilitating condition [4]. There
is currently no effective treatment, with single analgesics
usually failing to adequately treat the pain, meaning that
patients are offered available therapies in a stepwise and often
combinatorial fashion [5, 6]. One of the first-line treatments
is gabapentin [7], an analogue of the inhibitory neurotrans-
mitter 𝛾-aminobutyric acid (GABA), an anticonvulsant drug
which is also antiallodynic in neuropathic and inflammatory
pain states [8]. The underlying mechanisms of analgesia pro-
vided by this drug are not thoroughly understood. However,
gabapentin can interact with several targets, including the
𝛼2-𝛿 subunit of voltage-activated calcium channels [9] and
the L-amino acid transporters (LAT-1 and LAT-2; [10]) and
has been shown to reduce spinal microglial activation and
allodynia in rats with experimental diabetes [11, 12].
The pathogenesis of neuropathic pain involves changes
in neuronal activity in the peripheral and central nervous
systems and also activation of glial and immune cells [13, 14].
Glial cells are rapidly activated in response to peripheral
nerve injury [15–17] and are responsible for the release of
many inflammatory mediators, including chemokines and
cytokines important for the establishment and maintenance
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of neuropathic pain [13, 18]. In rodent models of diabetes,
microglia are activated in the dorsal horn of the lumbar spinal
cord [11, 19, 20] and their activation has been associated
with neuropathic pain. Whilst the intact blood-brain barrier
largely prevents circulating immune cells from crossing into
the parenchyma, permeability can be modulated by trauma
or inflammation, enabling recruitment and infiltration of
immune cells into the central nervous system (CNS). Periph-
eral injection of carrageenan into the hind paw, for example,
causes an increase in ICAM and VCAM expression in spinal
epithelium, changes in tight junction proteins, an increase in
brain-barrier permeability, and the consequent migration of
neutrophils into the CNS [21]. In both diabetic nephropathy
and retinopathy, increased leukostasis and infiltration have
been observed and are detrimental to symptom severity
[22, 23]. However, to our knowledge, no information exists
regarding the transmigration of neutrophils in the spinal cord
in painful diabetic neuropathy.
In this study, we identify an increase in L-selectin and in
the number of neutrophils present in the parenchyma of the
spinal cord of untreated diabetic rats, which could represent
a novel therapeutic target to explore in future studies.
2. Methods
2.1. Induction of Diabetes and Drug Delivery. All experiments
were carried out using mature adult male Sprague-Dawley
rats (495–570 g, bred at The Institute of Medical Science,
Aberdeen University) in accordance with the UK Animals
(Scientific Procedures) Act 1986. Diabetes was induced using
streptozotocin (STZ in sterile saline; 40mg/kg i.p.; 𝑛 =
12). Age- and weight-matched rats were used as nondiabetic
controls (𝑛 = 6). Diabetic rats were either untreated or treated
daily for 2 weeks with gabapentin (50mg/kg/day by gavage;
Spectrum Chemical Manufacturing Corp, Gardena) starting
6 weeks following STZ injection.
2.2. Behavioural Testing. After 8 weeks of diabetes and within
2 hours following gabapentin administration, the behavioural
response to mechanical and thermal stimulation of the hind
paw was assessed using an automatic Von Frey probe and
Hargreaves apparatus, respectively (Ugo Basile, Italy). All
animals were habituated to the tester and the environment
prior to testing. The Von Frey probe was set to deliver
an initial 2 g force over 8 seconds. The stimulus was then
increased by a 0.2 log unit increment if there was no response
or decreased by the same increment if the animal responded.
Testing was performed on each foot and a 50% threshold was
determined [24, 25]. An average value for the 2 feet was then
calculated. For thermal testing, the time taken for the animal
to remove its hind paw from the infrared heat stimulus was
recorded 3 times for each foot. The first reading from each
foot was discarded, and the mean response time was then
calculated.
2.3. Tissue Processing. Rats were killed by isoflurane overdose
1 day after their final behavioural assessment and dose
of gabapentin. Blood glucose levels were measured using
an Ascensia Breeze 2 machine (Bayer, UK) from blood
obtained by cardiac puncture. The lumbar (L3–L6) spinal
cord region was rapidly dissected and postfixed in ice-cold
4% paraformaldehyde for 4 hours or frozen on dry-ice.
2.4. Immunohistochemistry. Fixed lumbar spinal cord was
cryoprotected at 2–8∘C in 10% sucrose in 0.1M phosphate
buffer for 18–24 hours followed by 30% sucrose in 0.1M
phosphate buffer for a further 18–24 hours. Tissue was then
embedded in OCT embedding matrix media (Thermo Shan-
donLtd., UK) and frozen ondry-ice. Transverse sectionswere
cut by cryostat (16 𝜇m) and thaw-mounted onto Superfrost
Plus Slides (Fisher Scientific, UK).
For staining of microglia, one group of slides were first
incubated twice for 15 minutes each (0.1M PBS, 20% (v/v)
methanol, 1.5% (v/v) hydrogen peroxide) for peroxidase-
conjugated studies. After washing (phosphate buffered saline
(PBS)), nonspecific binding in all slides was blocked for an
hour (5% goat serum in 0.2% triton-X in PBS at room temper-
ature) and sections were incubated overnight with primary
antibody for ionized calcium binding adaptor molecule 1
(rabbit anti-Iba1; Wako, Germany; 1/1000 in 5% goat serum
in 0.2% triton-X PBS at 2–8∘C;). Biotinylated or fluorescein
conjugated anti-rabbit secondary antibody (1/500 in 5% goat
serum in 0.2% triton-X PBS; Vector, USA) was allowed to
bind primary antibody for 1.5 hours at room temperature.
Fluorescent sections were washed then either mounted in
Vectorshield containing DAPI (Vector, USA) or incubated
for 1 hour at room temperature with AvidinBiotin solution
as per manufacturer’s instructions (VECTASTAIN ABC
system, Vector, USA). Immunoreactivity was then visualised
using DAB as per manufacturer’s instructions (Vector, USA).
Sections were dehydrated through a 50, 70, 90%, and absolute
ethanol series followed by xylene washes, before mounting
with Pertex mounting media (CellPath, UK).
For staining of neutrophils and blood vessels, sections
were washed and nonspecific binding and autofluorescence
were reduced (0.1M glycine, 5% goat serum, 5% donkey
serum in 0.3% triton-X in PBS; for 2 hours at room temper-
ature). Primary antibodies for rabbit anti-neutrophil serum
(SJC; 1/10,000; gift A. De´nes, (University of Manchester, UK)
from D. Anthony and S. Campbell, University of Oxford,
UK, produced [26]) and mouse anti-human laminin (1/1000;
Millipore, UK) were applied overnight (in 2.5% goat serum,
2.5% donkey serum 0.3% triton-X in PBS, 2–8∘C). After
washing, primary antibodies were visualised with donkey
anti-rabbit secondary Cyanine- 3-(Cy3-) conjugated anti-
body (1/1000; Jackson ImmunoResearch, USA) and goat anti-
mouse conjugated Alexa Fluor 488 (1/1000; Invitrogen Life
Technologies, UK) for 2 hours at room temperature (5% goat
serum, 5% donkey serum in 0.3% triton-X in PBS).
Negative control sections were produced with each batch
of immunostaining, with the absence of primary antibody.
Staining was visualised on a Leica DMR microscope and
images captured using a Hamamatsu digital C4742-95 digital
camera (Japan). Higher power fluorescence images were
taken using an Olympus BX51 upright microscope and
Coolsnap EZ (Photometrics, USA) camera runningMetaVue
Software (Molecular Devices, USA), or a Delta Vision
(Applied Precision, USA) restoration microscope using a
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60x objective, captured using a Coolsnap HQ (Photometrics,
USA) camera with a𝑍 optical spacing of 0.2𝜇m. Raw images
were then deconvolved using Softworx (Applied Precision,
USA). Highmagnification images of microglia were captured
on a Panoramic 250 slide scanner (3DHISTECH Ltd., Hun-
gary), using a 20x objective and visualised using Pannoramic
Viewer 1.15 software (3DHISTECH Ltd., Hungary).
2.5. Cytokine Profile Array. Spinal cords were homogenized
in ice-cold lysis buffer (25mM Tris HCl pH 7.4, 15mM
NaCl, 10mM NaF, 10mM Na Pyrophosphate, 2mM EDTA,
0.2mM Na4OV3, 1 mM PMSF, Protease Inhibitor Cocktail
(1 : 200; Sigma Aldrich, UK)) using the FastPrep bead beater
system (MP Biomedicals, USA). The protein concentration
of each sample was determined using a BCA assay (Pierce
Biotechnology, UK) and 350𝜇g of lysate was loaded per
membrane (Rat Cytokine Array Panel A, R&D Systems,
UK), as per manufacturer’s instructions. Cytokine levels were
visualised and quantified using IRDye 800CW Streptavidin
secondary antibody (1/2000 in assay buffer 6; Li-Cor,UK) and
captured on an Odyssey Infrared Imaging System. Results
were analysed using Odyssey 2.1 Software (Li-Cor, UK) and
all absorbance values were corrected for background.
2.6. L-Selectin ELISA. Spinal cord lysates from control,
untreated diabetic and gabapentin-treated rats (75𝜇g of
protein) were loaded in duplicate and analysed for L-selectin
content using a commercial ELISA kit (rat L-selectin/CD62L
DuoSet, R&D Systems, UK).
2.7. Spinal Cord Neutrophil Analysis. To determine the num-
ber of infiltrating neutrophils, dual labelling was used to
visualise both blood vessels and neutrophils present within
the parenchyma. Only neutrophils outside of blood ves-
sels were measured, that is, not intraluminal neutrophils.
Parenchymal cell counts were performed on 4-5 lumbar
spinal cord sections per animal (𝑛 = 6) and expressed asmean
number of neutrophils per section.
2.8. Microglia Analysis. Iba1-immunoreactive cell morphol-
ogy was analysed from DAB-labelled sections using the
method described by Calvo et al. [27]. Briefly, SigmaScan
Pro software (SPSS) was used to overlay a grid with squares
measuring 10000 𝜇m2 on regions of the dorsal horn. A
minimum of 5 randomly selected squares from a minimum
of 4 spinal cord sections per animal were analysed. Only
cells with a clearly visible cell body were analysed. Microglia
whose processes were greater than double the cell-body
length were deemed “surveying.”Those cells where processes
were less than double the cell-body lengthwere categorised as
“effector.” Results are presented as the percentage ofmicroglia
displaying an “effector” morphology. Iba-1-immunoreactive
cells present in the superficial dorsal horn were counted from
3–5 sections per animal and expressed as number of cells per
1 × 105 𝜇m2.
2.9. Statistical Analysis. Data are expressed as mean values ±
standard deviation, unless otherwise stated. A Kruskal-Wallis
ranking test was carried out on the Von Frey, and L-selectin
ELISA data and 1-wayANOVAwith Bonferroni post hoc tests
were used to analyse all other data using GraphPad Prism 4
software (GraphPad software, USA).
3. Results
3.1. Gabapentin Reduces Hypersensitivity in STZ-Diabetic
Rats. Rats with STZ-induced diabetes displayed mechanical
allodynia at 8 weeks compared with age-matched controls
(control: 37.0 g ± 3.2 versus untreated diabetic: 17.4 g ± 4.1,
𝑝 < 0.001; Figure 1(a)). Gabapentin-treated diabetic rats
(50mg/kg/day for 2 weeks from 6 weeks after STZ) did
not demonstrate the same degree of mechanical sensitivity,
as no significant difference was observed between control
and gabapentin-treated diabetic rats at 8 weeks (30.6 g ±
5.0, Figure 1(a)). In addition, diabetes-associated thermal
hyperalgesia was prevented with gabapentin (untreated dia-
betic: 7.8 s ± 0.6 versus gabapentin-treated diabetic: 10.1 s ±
1.6, 𝑝 < 0.05; Figure 1(b)). Gabapentin therefore protects
against diabetes-associated allodynia and thermal hyperalge-
sia, without affecting terminal blood glucose levels (control:
8.1 ± 0.4mmol/L; untreated diabetic: 34.1 ± 4.8mmol/L (𝑝 <
0.001); diabetic + gabapentin: 39.2 ± 7.1mmol/L (𝑝 < 0.001)
compared with blood glucose levels in control rats: 1-way
ANOVA with Bonferroni post hoc tests).
3.2. Diabetes-Induced Increase in L-Selectin in the Spinal
Cord is Prevented by Gabapentin. An increase in the levels
of proinflammatory cytokines has previously been reported
in the rat spinal cord at early time points of diabetes (4-
5 weeks after STZ: [28, 29]). We therefore conducted a
cytokine profiling array using lumbar spinal cord samples
(Figures 2(a)–2(c); Table 1) to determine which were altered
at the 8-week time point of diabetes. The levels of classical
“proinflammatory” cytokines such as TNF-𝛼 (Figure 2(d)),
IL-1𝛼 (Figure 2(e)), and IL-1𝛽 (Figure 2(f)) were not sig-
nificantly different in spinal cord samples from diabetic
rats. Indeed, the only significant change (the full panel of
results of 29 cytokines is shown in Table 1) was in the
expression of L-selectin, which was significantly increased by
55% in spinal cords from untreated diabetic rats compared
to control rats; this increase was prevented by gabapentin
(Figure 2(g)). This observation was validated using ELISA
(untreated diabetic: 0.14 ± 0.13 𝜌g L-selectin/𝜇g spinal cord
protein versus gabapentin-treated diabetic: 0.04 𝜌g ± 0.02 L-
selectin/𝜇g spinal cord protein; 𝑝 < 0.05; Figure 2(h)).
3.3. Glial Cell Profiling in the Dorsal Horn of Rats with 8Weeks
of Experimental Diabetes. A change in spinal microglial
number and morphology has previously been reported at
early time points of diabetes (2–4 weeks after STZ: [11, 20]).
Here, we examined Iba-1-immunopositivemicroglia at a later
time point in the lumbar spinal cord of control, untreated
diabetic, and diabetic rats treated with gabapentin (Figure 3).
At 8weeks after STZ, therewas a small but significant increase
in the numbers of Iba-1-positive cells present in the superficial
dorsal horn of untreated diabetic rats (Figures 3(a)–3(d);
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Figure 1: Gabapentin corrects diabetes-induced hypersensitivity. (a) Mechanical allodynia was observed in untreated diabetic rats (8 weeks
after STZ), whilst diabetic rats treated with gabapentin showed near-control thresholds. Data are displayed as box and whisker plots, ∗∗∗𝑝 <
0.001, in a Kruskal-Wallis test with Dunn’s post hoc tests. (b)Thermal hyperalgesia was determined using a Hargreaves device; again diabetic
rats treated with gabapentin showed near-control thresholds ∗𝑝 < 0.05, in a 1-way ANOVA with Bonferroni post hoc tests. Data represent
mean latency + SD; 𝑛 = 6.
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Figure 2: L-Selectin is increased in the spinal cord of diabetic rats. Cytokine proteome arrays were used to assay levels of 29 cytokines in (a)
control, (b) untreated diabetic, and (c) gabapentin-treated diabetic rats.Therewas no change in the spinal levels of classically proinflammatory
cytokines such as (d) TNF-𝛼, (e) IL-1𝛼, or (f) IL-1𝛽 (g). However, L-selectin (highlighted in box in (a)–(c)) was significantly increased in
diabetic rat lumbar spinal cord, and this increasewas ameliorated by treatmentwith gabapentin (∗𝑝 < 0.05 in a 1-wayANOVAwithBonferroni
post hoc tests. Mean optical densities + SD are displayed; 𝑛 = 4). (h) This was independently confirmed with an ELISA; levels of L-selectin
were reduced when diabetic rats were treated with gabapentin (∗𝑝 < 0.05 in a Kruskal-Wallis test with Dunn’s multiple comparison test;
𝑛 = 5-6).
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Table 1: Rat spinal cord cytokine proteome array. The levels of
29 cytokines in the lumbar spinal cord of control, diabetic, and
gabapentin-treated diabetic rats. Mean values ± SD are displayed.
𝑛 = 4. ∗𝑝 < 0.05 in a 1-way ANOVA.
Name
Mean OD ± SD
𝑝 value
Control Diabetic Diabetic +gabapentin
IL-1𝛼 0.30 0.09 0.37 0.15 0.35 0.07 0.60
IL-1𝛽 0.32 0.07 0.33 0.03 0.32 0.09 0.96
IL-1ra 0.30 0.03 0.37 0.02 0.33 0.05 0.09
IL-2 0.25 0.03 0.26 0.06 0.36 0.09 0.10
CINC-1 0.39 0.21 0.51 0.34 0.56 0.24 0.68
CINC-2 0.10 0.02 0.12 0.02 0.13 0.05 0.40
CINC-3 0.31 0.04 0.37 0.04 0.33 0.02 0.12
IFN-𝛾 0.31 0.05 0.29 0.02 0.27 0.02 0.19
IL-3 0.26 0.09 0.26 0.05 0.28 0.08 0.91
IL-4 0.23 0.08 0.25 0.06 0.27 0.08 0.74
IL-6 0.25 0.04 0.24 0.03 0.20 0.04 0.26
IL-10 0.25 0.08 0.22 0.03 0.24 0.04 0.82
CNTF 6.52 1.91 8.68 2.50 9.49 3.47 0.32
sICAM-1 9.18 3.28 13.10 2.74 12.80 2.63 0.15
Thymus
chemokine 19.90 0.36 23.20 3.03 17.10 5.85 0.13
Fractalkine 1.02 0.24 1.00 0.18 1.02 0.27 0.99
GM-CSF 0.37 0.20 0.34 0.06 0.28 0.04 0.55
RANTES 0.29 0.06 0.40 0.13 0.40 0.09 0.22
TIMP-1 0.46 0.28 0.75 0.43 0.96 0.94 0.54
TNF-𝛼 0.10 0.03 0.12 0.03 0.13 0.04 0.38
VEGF 0.56 0.17 0.41 0.02 0.49 0.03 0.07
CXCl5 0.71 0.1 1.1 0.31 0.72 0.15 0.07
MIG 0.36 0.07 0.35 0.04 0.33 0.07 0.81
IL-13 0.26 0.17 0.18 0.04 0.22 0.05 0.57
IL-17 0.22 0.04 0.24 0.06 0.31 0.05 0.10
MIP-1𝛼 0.13 0.02 0.14 0.01 0.13 0.03 0.38
MIP3𝛼 0.21 0.04 0.21 0.01 0.19 0.02 0.32
IP-10 0.27 0.04 0.33 0.01 0.30 0.03 0.06
L-Selectin 0.99 0.18 1.53 0.32 0.87 0.20 0.01∗
IL-1𝛼: interleukin-1 alpha; IL-1𝛽: interleukin-1 beta; IL-1ra: interleukin-
l receptor antagonist; IL-2: interleukin-2; IL-3: interleukin-3; IL-4:
interleukin-4; IL-6: interleukin-6; IL-10: interleukin-10; CNTF: ciliary
neurotrophic factor; sICAM: soluble intercellular adhesion molecule;
CINC-1: Cytokine-Induced Neutrophil Chemoattractant-1; CINC-2:
Cytokine-Induced Neutrophil Chemoattractant-2; CINC-3: Cytokine-
Induced Neutrophil Chemoattractant-3; IFN-𝛾: interferon-gamma; GM-
CSF: granulocytemacrophage colony stimulating factor; RANTES: regulated
upon activation, normal T-cell expressed and presumably secreted; TIMP-1:
tissue inhibitor of metalloproteinases-1; TNF-𝛼: tumour necrosis factor;
VEGF: vascular endothelial growth factor; CXCl5: lipopolysaccharide-
induced CXC; MIG: monokine induced by gamma interferon; IL-13:
interleukin-13; IL-17: interleukin-17; MIP-1𝛼: Macrophage Inflammatory
Protein-1 alpha; MIP-3𝛼: Macrophage Inflammatory Protein-3 alpha; IP-10,
interferon-gamma-induced protein-10 kDa/CXC motif chemokine 10.
𝑝 < 0.05 1-way ANOVA with Bonferroni post hoc tests);
however, cell morphology was equivalent in all treatment
groups (Figure 3(e); control: 67% ± 4.6: untreated diabetic:
61% ± 8.1; gabapentin-treated diabetic 63% ± 4.8 microglia
had “effector”morphology; i.e., processes were less than twice
the length of the cell body).
3.4. Increased Numbers of Neutrophils Are Present in the
Spinal Cord Parenchyma of Diabetic Rats, Which Is Ame-
liorated with Gabapentin Treatment. The diabetes-associated
upregulation of L-selectin, an adhesion molecule impor-
tant for neutrophil transmigration [30], suggested possible
immune cell recruitment/infiltration into the spinal cord.
Therefore, immunohistochemistry was performed to identify
whether neutrophils had infiltrated the spinal cord. The
spinal cord parenchyma of untreated diabetic rats (arrows,
Figures 4(b), 4(e), and 4(h)) containedmore neutrophils than
control (Figures 4(a), 4(d), and 4(g)) and gabapentin-treated
(Figures 4(c), 4(f), and 4(i)) rats. Since rats were not tran-
scardially perfused prior to tissue harvest, only neutrophils
present in spinal parenchyma (arrows, Figures 4(k) and 4(l))
were counted and not those contained within blood vessels
(asterisks, Figures 4(j) and 4(l)). There was a significant
increase in the number of parenchymal neutrophils through-
out the spinal cord in untreated diabetic rats compared with
control rats (untreated diabetic: 2.60 ± 1.4 versus control:
0.53±0.55; Figure 4(m)𝑝 < 0.01). Interestingly, this increase
was not observed in diabetic animals treated with gabapentin
(1.03±0.63, 𝑝 < 0.05 compared with untreated diabetic rats).
4. Discussion
In this study, we demonstrate an increase in the levels of
L-selectin, an adhesion molecule important for neutrophil
transmigration, in the lumbar spinal cord after 8 weeks of
diabetes. In addition, we show an increase in the number of
parenchymal neutrophils in the spinal cord of diabetic rats.
Together, these data suggest a role for dysregulated L-selectin
and spinal vasculature in diabetes that leads to an increase in
infiltrating neutrophils in experimental diabetic neuropathy,
which is ameliorated by treatment with gabapentin.
The cytokine profiling array did not show diabetes-
associated increases in classic proinflammatory cytokines
such as IL-1𝛽, TNF-𝛼, fractalkine, and IL-6 cytokines, which
are associated with microgliosis and hyperalgesia [11, 20, 28,
29, 31, 32].Microglial activation has been associatedwith pain
in a number of neuropathy models, notably traumatic nerve-
injury models [14] and early time points of STZ-diabetes
[11, 31]. However, microgliosis was not associated with viral-
induced hypersensitivity [33] and minimal in a nucleoside
reverse transcriptase inhibitor- (stavudine-) induced HIV
hypersensitivity model [34]. Our finding that there was a
small increase in microglial number, but no change in mor-
phology at 8 weeks, perhaps indicates why we did not detect
increases in the proinflammatory cytokines in our arrays but
does not preclude the possibility that microglial activation
may have occurred at an earlier time point. It is also possible
that subtle changes in proinflammatory cytokines specifically
6 Journal of Diabetes Research
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Figure 3: Microglial changes in the spinal cord of control, untreated diabetic, and gabapentin-treated diabetic rats. Representative
photomicrographs of the L4/5 dorsal horn of the spinal cord of (a) control, (b) untreated diabetic, and (c) diabetic rats treated with gabapentin
(a–c), micrographs (and insets) show examples of typical Iba1-immunoreactivity. Scale bars represent 100 𝜇m (mainmicrograph, (a)–(c)) and
25 𝜇m (insets (a)–(c)). Microglial numbers are increased in the superficial ((d),∗𝑝 < 0.05 1-way ANOVA Bonferroni post hoc tests) but not
deep (e) dorsal horn of diabetic rats; however, morphology of microglia was not significantly different (e).
within the dorsal horn may have not been detected, as whole
lumbar spinal cord lysates were used in our assay.
However, interestingly, we found a significant increase
in L-selectin (a type I cell adhesion molecule which is
constitutively expressed on the cell surface ofmost circulating
leukocytes [30]) in spinal cords from diabetic rats, which
was not evident in spinal cords from diabetic rats treated
with gabapentin. L-Selectinmediates the initial tethering and
rolling of leukocytes along activated endothelial cells and
then the transendothelial migration of leukocytes through
the vasculature. L-Selectins are cleaved from the cell surface
by the action ofADAM17 (disintegrins andmetalloproteinase
17) or TACE (TNF-𝛼 converting enzyme), a process known as
“shedding,” which may dramatically regulate migratory cell
behaviour [35].
Neutrophils are one of the first types of peripheral
immune cell to attend sites of inflammation following injury
or infection [36]. They are important in mounting an ini-
tial immune response, able to produce both proinflamma-
tory mediators, as well as present antigen to T-cells [37].
In experimental nerve-injury models, the recruitment of
immune cells both peripherally and centrally is an important
mechanism underlying establishment and maintenance of
neuropathic pain [38]. Neutrophil migration into the CNS
is well characterised in spinal cord injury models [39], and
reductions in leukocyte infiltration in the CNS have been
linked to reductions in neuropathic pain [40]. The reac-
tive glycolytic metabolite methylglyoxal is increased in the
plasma of both STZ-diabetic mice and diabetic patients [41].
Interestingly, peripheral injection of methylglyoxal induces
leukocyte recruitment to the microvasculature of the injec-
tion site and approximately 90% of the recruited cells are
neutrophils [42], suggesting that recruitment of this cell
type may be particularly important in diabetes. In diabetic
retinopathy, higher numbers of CD45+ immune cells have
been recorded in the retina of diabetic mice compared with
controls [43]. In diabetic rats too, increased numbers of
leukocytes are associated with retinal endothelial cells, when
compared with retina from control rats [44]. Similarly, an
increase in neutrophils in the kidney has been described in
mice with diabetic nephropathy [45]. Increased numbers of
neutrophils in the parenchyma of spinal cords from diabetic
rats compared with controls indicate commonality between
the three major diabetic complications.
This increase in spinal neutrophil recruitment in dia-
betes could be a consequence of altered afferent activity,
spinal sensitisation, structural damage, or altered blood-brain
barrier function. Interestingly, the reduction in numbers
of neutrophils within the spinal cord parenchyma after
gabapentin followed the reduction in allodynia and thermal
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Figure 4: Diabetes is associated with an increase in neutrophil numbers within the spinal cord parenchyma, which is ameliorated with
gabapentin treatment. (a–i) There is an increase in antineutrophil immunoreactivity within the dorsal horn (a–c), central region (d–f),
and ventral horns (g–i) of untreated diabetic rats (arrows, (b), (e), and (h), scale bar represents 100 𝜇m.). Dual immunofluorescence with
antilaminin (green) to label blood vessels reveals the presence of intraluminal (asterisks, (j) and (l)) and parenchymal neutrophils (arrows,
(k) and (l)). Only parenchymal neutrophils (i.e., those not associatedwith a vessel) were counted (m) and revealed an increase in neutrophils in
the spinal cord of untreated diabetic rats and revealed that gabapentin treatment reduced the numbers to near-control levels ((m), ∗𝑝 < 0.05,
∗∗𝑝 < 0.01 in a 1-way ANOVA with Bonferroni post hoc tests. 𝑛 = 6).
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hyperalgesia in diabetic rats. The reduced numbers of spinal
neutrophils in diabetic rats treated daily with gabapentinmay
be a downstream consequence of the transitory analgesic
effects of gabapentin ([46]). This may be through inhibition
of excitatory postsynaptic currents from dorsal horn neurons
or a reduction inmicrogliosis persisting for a sufficient length
of time to prevent neutrophil infiltration into the spinal cord.
It will be interesting for future studies to examine whether
gabapentin has a direct effect on L-selectin expression.
This effect may be via the spinal vasculature, neutrophil
migration across the endothelium, and/or release from the
bone marrow. Indeed, in an induced paw edema model,
gabapentin treatment reduced both leukocyte counts and
MPO activity (neutrophil marker) in the foot [47]. Depletion
of circulating neutrophils has also previously been shown
to attenuate the development of hyperalgesia following a
peripheral nerve injury [48]. We suggest that future studies
will be important to determine the impact of blocking neu-
trophil recruitment to the spinal cord on neuropathic pain
in diabetes. Using intrathecal L-selectin function-blocking
antibodies or inhibitors may provide valuable mechanistic
evidence linking spinal L-selectin expression and neutrophil
invasion with the pathogenesis of diabetic neuropathy.
In conclusion, this current work highlights the impor-
tance of considering not only glial activation, changes in
ion channel expression, and altered neuronal activity in
painful diabetic neuropathy, but also the effect of immune cell
infiltration into the spinal cord; this may open more avenues
by which to direct future therapeutic targeting.
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